- Home
- IFRX vs TOYO Comparison
IFRX vs TOYO Comparison
Compare IFRX & TOYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- TOYO
- Stock Information
- Founded
- IFRX 2007
- TOYO 2022
- Country
- IFRX Germany
- TOYO Japan
- Employees
- IFRX N/A
- TOYO N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- TOYO
- Sector
- IFRX Health Care
- TOYO
- Exchange
- IFRX Nasdaq
- TOYO NYSE
- Market Cap
- IFRX 143.7M
- TOYO 115.2M
- IPO Year
- IFRX 2017
- TOYO N/A
- Fundamental
- Price
- IFRX $2.24
- TOYO $3.37
- Analyst Decision
- IFRX Strong Buy
- TOYO
- Analyst Count
- IFRX 1
- TOYO 0
- Target Price
- IFRX $8.00
- TOYO N/A
- AVG Volume (30 Days)
- IFRX 401.6K
- TOYO 2.6M
- Earning Date
- IFRX 11-08-2024
- TOYO 02-21-2025
- Dividend Yield
- IFRX N/A
- TOYO N/A
- EPS Growth
- IFRX N/A
- TOYO N/A
- EPS
- IFRX N/A
- TOYO 0.76
- Revenue
- IFRX $187,930.00
- TOYO $200,455,385.00
- Revenue This Year
- IFRX $435.15
- TOYO N/A
- Revenue Next Year
- IFRX $180.44
- TOYO N/A
- P/E Ratio
- IFRX N/A
- TOYO $4.42
- Revenue Growth
- IFRX 177.12
- TOYO N/A
- 52 Week Low
- IFRX $1.17
- TOYO $1.36
- 52 Week High
- IFRX $2.82
- TOYO $15.61
- Technical
- Relative Strength Index (RSI)
- IFRX 52.76
- TOYO N/A
- Support Level
- IFRX $1.93
- TOYO N/A
- Resistance Level
- IFRX $2.74
- TOYO N/A
- Average True Range (ATR)
- IFRX 0.25
- TOYO 0.00
- MACD
- IFRX -0.06
- TOYO 0.00
- Stochastic Oscillator
- IFRX 34.88
- TOYO 0.00
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries is engaged in research and development, production, and sales of solar cells.